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There is increasing evidence that a low vitamin D status may be an important and hitherto neglected factor of
cardiovascular disease. This review is an overview of the current body of literature, and presents evidence of the
mechanisms through which vitamin D deficiency affects the cardiovascular system in general and the heart in particular.
Available data indicate that the majority of congestive heart failure patients have 25-hydroxyvitamin D deficiency.
Furthermore, the low serum 25-hydroxyvitamin D level has a higher impact on hypertension, coronary artery disease an
on the occurrence of relevant cardiac events. A serum 25-hydroxyvitamin D level below 75 nmol/l (30 ng/l) is generally
regarded as vitamin D insufficiency in both adults and children, while a level below 50 nmol/l (20 ng/l) is considered
deficiency. Levels below 50 nmol/l (20 ng/l) are linked independently to cardiovascular morbidity and mortality.
 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Abbreviations
25(OH) D 25-hydroxyvitamin D
CAD coronary artery disease
HTN hypertension
CHF congestive heart failure
VDR vitamin D receptor
RAAS renin-angiotensin-aldosterone system
IL interleukin
TNF tumor necrosis factor
NYHA New York Heart Association
NT pro-BNP N-terminal of the prohormone brain natriuretic
peptide
NT-proANP N-terminal of the prohormone atrial natriuretic
peptide
LVEF left ventricle ejection fraction
LURIC Ludwigshafen Risk and Cardiovascular Health
(LURIC) Study
HR hazard ratio
OR Odds Ratio
RR Relative Ratio
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VITAMIN D DEFICIENCY PLAYS AN IMPORTANT ROLE IN CARDIAC DISEASE
AND AFFECTS PATIENT OUTCOME: STILL A MYTH OR A FACT THAT NEEDS
EXPLORATION?Introduction
Vitamin D deficiency is widely prevalent in theUnited States and worldwide [1]. Low levels
of 25-hydroxy vitamin D [25(OH) D], the principal
circulating storage form of vitamin D, are present
in one third to one half of otherwise healthy mid-
dle-aged to elderly adults [1–3]. Although most
consequences of vitamin D deficiency involve
the musculoskeletal system, there is a growing
body of evidence suggesting that low levels of
vitamin D may adversely affect the cardiovascular
system [4]. A serum 25-hydroxyvitamin D level
below 75 nmol/l (30 ng/l) is generally regarded as
vitamin D insufficiency in both adults and chil-
dren, while a level below 50 nmol/l (20 ng/l) is
considered deficiency in both populations [5,6].
Vitamin D deficiency, which is affected by
multiple factors (Table 1), appears to have an
association with diverse cardiac diseases starting
with its direct effect on the cardiac cell, its
association with coronary artery disease (CAD),
and its risk factors such as diabetes and hyperten-
sion (HTN); ending at last and probably not least
in its relation with congestive heart failure
(CHF). Similarly, there is some evidence that links
vitamin deficiency to increased risk of stroke.
This article is an overview of the current data
describing the effect of vitamin D on the cardiac
cell and the relationship of its deficiency with
HTN, CAD, and heart failure. We compare vita-
min D to its clinical and laboratory markers as well
as to clinical outcomes and cardiac events. Finally,
we explore the impact of vitamin D deficiency on
cardiovascular outcomes including death, cardiac
death, stroke, and myocardial infarction.Methods
Relevant studies were identified through
electronic searches of MEDLINE and theTable 1. Examples of some causes of vitamin D deficiency or resist
Causes of vitamin D deficiency or resistance
Deficient intake or absorption D
In
M
G
S
P
Defective 25-hydroxylation L
A
A
Loss of vitamin D binding protein N
Defective 1-alpha 25-hydroxylation H
C
1-
Defective target organ response to calcitriol Hdatabases of the Cochrane Central Register of
Controlled Trials. The search used the terms ‘‘car-
diovascular disorders,’’ ‘‘cardiovascular disease,’’
‘‘hypertension,’’ ‘‘coronary artery disease,’’ or
‘‘congestive heart failure’’ paired with ‘‘vitamin
D deficiency’’ and ‘‘calcitriol’’. In addition, we
searched bibliographies of relevant studies,
reviews and editorial letters between 1990 and
2015 for articles in English. We reviewed the refer-
ences to identify the studies addressing the role of
vitamin D hemostasis in the pathogenesis of car-
diovascular disease, and the impact of vitamin D
deficiency and supplementation on HTN, CAD,
CHF, and cardiovascular outcomes. Although
human studies were of interest in regards to out-
comes, many animal model studies were included
for the purpose of the pathogenesis of vitamin D
deficiency role in cardiovascular disease. Out of
3026 articles, 88 were identified as meeting our cri-
teria and were reviewed. Of those 88, 43 were used
in the final version of this article.ance.
ietary
adequate sunlight exposure
alabsorption
astrectomy
mall bowel disease
ancreatic insufficiency
iver disease/failure
lcoholic cirrhosis
nticonvulsants
ephrotic syndrome
ypoparathyroidism
hronic kidney disease/failure
alpha hydroxylase deficiency (Vitamin D-dependent rickets type 1)
ereditary vitamin D-resistant rickets (Vitamin D-dependent rickets, type 2)
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2015;27:264–271Vitamin D deficiency and the pathogenesis
of cardiovascular disease
The contractile properties of cardiac cells are
mainly controlled by the direct interaction
between calcium, the contractile proteins, actin
and myosin, and the intracellular handling of cal-
cium. The extracellular calcium homeostasis
affected by vitamin D levels impact the intracellu-
lar calcium and can indirectly influence cardiac
cell contractility [7].
Calcitriol, the active vitamin D form (1,25-dihy-
droxyvitamin D), impacts the function of almost
all body cells including cardiac cells, endothelial
cells, and vascular smooth muscle cells through
the cytosolic vitamin D receptor (VDR). This
impact varies among these cells but is crucial in
cardiac cells as they depend solely on the circulat-
ing blood concentration of calcitriol secondary to
the absence of an enzymatically active 25-hydrox-
yvitamin D-1 [alpha]-hydroxylase system [8,9].
The absence of VDR receptors, therefore, has
many adverse effects on cardiac cells. Isolated car-
diac cells from VDR knockout mice are noted to
have accelerated rates of contraction and relax-
ation that are not affected by calcitriol levels when
compared to control mice [10,11]. Furthermore,
cellular hypertrophy of heart myofibrils resulting
in cardiomegaly was noticed in VDR knockout
mice [12]. This can be explained by the fact that
tissue inhibitors of matrix metalloproteinases
were significantly under-expressed in VDR knock-
out mice compared to control mice [12]. Without
this inhibition of matrix metalloproteinases, the
extracellular matrix remodeling mediated by
matrix metalloproteinases leads to progressive left
ventricular remodeling, dilation, and heart failure.
Calcitriol, through VDR receptors, has sig-
nificant impact on the morphology, proliferation,
and growth of cardiac cells. Treatment with
calcitriol increases the expression of the cardiac
muscle protein, myotrophin, reduces expression
of atrial natriuretic peptide, and increases expres-
sion and nuclear localization of the VDR in these
cells [11,13]. Vitamin D3 deficiency in rats was
associated with significant hypocalcaemia, an
increase in plasma parathyroid hormone, a reduc-
tion in the size of myofibrils, and accumulation of
collagen fibers, resulting in interstitial fibrosis [14].
However, calcitriol supplementation may prevent
the development of cardiac hypertrophy. In rats
with spontaneously hypertensive heart failure,
calcitriol treatment resulted in lower heart weight,
myocardial collagen levels, left ventricular dia-
meters, and cardiac output compared with
untreated rats [11].VDR receptors have different genotypes. A
recent study evaluated the association between
VDR gene variants and ischemic stroke in an
Asian Indian population. Among the three single
nucleotide polymorphisms of the VDR gene that
were genotyped using PCR-RFLP method, and
studied for the association (Fok I, Apa I, and
Taq I), both Apa I and Taq I polymorphisms
were not found to be associated with ischemic
stroke. However, presence of ff genotype of
Fok I was found to confer 2.97-fold risk of
ischemic stroke (95% CI = 1.16–7.63, p = 0.02) as
compared to FF genotype of Fok I. This asso-
ciation was found to be independent of various
demographic and important biochemical covari-
ates including age, gender, smoking, alcohol
intake, BMI, and serum glucose, lipid profile,
insulin, 25-hydroxyvitamin D, and plasma nitric
oxide levels [OR = 2.27, 95% CI = 1.25–4.09,
p = 0.01] [15].Vitamin D deficiency and hypertension
HTN is associated with inappropriate stimula-
tion of the renin-angiotensin-aldosterone system
(RAAS). Calcitriol is known to be one of the
negative endocrine regulators of RAAS [16,17].
In VDR receptor knockout mice, HTN was more
prevalent, probably secondary to the stimulation
of RAAS as it was corrected by angiotensin-con-
verting enzyme inhibitors and angiotensin II
receptor antagonists [16,17]. In several trials, cal-
citriol supplementation was shown to reduce
plasma renin activity, angiotensin II levels, blood
pressure, and myocardial hypertrophy [16,18]. It
has been demonstrated that regular exposure to
ultraviolet B radiation increases circulating
25(OH) D above a level of 100 nmol/l and
significantly reduces blood pressure by
approximately 6 mmHg in hypertensive patients
with initial 25(OH) D levels of 26 nmol/l within
an intervention period of six weeks [19]. In
another study, vitamin D deficient elderly wom-
en who were supplemented with calcium and
20 lg vitamin D3 daily had an increase in serum
25(OH) D of 20 nmol/l (p < 0.01), a decrease in
serum parathyroid hormone of 17% (p < 0.05), a
decrease in systolic blood pressure of 9.3%
(p < 0.025), and a decrease in heart rate of 5.4%
(p < 0.025) compared to those who were supple-
mented with calcium alone [20]. Therefore, a nor-
mal level of circulating calcitriol is crucial not
only for calcium homeostasis, but also for the
homeostasis of electrolytes, volume, and blood
pressure.
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Many studies show an association of vitamin D
deficiency with well-established atherosclerosis
risk factors (Fig. 1), including obesity, glucose
intolerance, metabolic syndrome, HTN, and
hyperlipidemia [21–23]. The Third National
Health and Nutrition Examination Survey, a
cross-sectional representative sample of the U.S.
population, also showed a significant increase in
the prevalence of HTN [OR = 1.30 (1.13–1.49);
p < 0.001], diabetes mellitus [OR = 1.73 (1.38–2.16);
p < 0.001], obesity [OR = 2.29 (1.99–2.63);
p < 0.001], and hypertriglyceridemia [OR = 1.47
(1.30–1.65); p < 0.001] in patients with vitamin D
levels of less than 21 ng/mL compared to those
with levels higher than 37 ng/mL (p < 0.001).[23]
That association was further supported by a
recent study from the University of Utah that
linked vitamin D deficiency to an increased risk
of hyperlipidemia (HR = 1.12, p = 0.002), diabetes
(HR = 1.33, p < 0.0001), and HTN (HR = 1.26,
p < 0.0001) in vitamin D deficient individuals [22].
The presumed role of vitamin D in the patho-
genesis of CAD is not necessarily linked only to
atherosclerosis, but may involve vascular calcifica-
tion. The basis of this presumption comes from
patients with end-stage renal disease. As a conse-
quence of reduced renal calcitriol synthesis, in
addition to other factors, secondary hyperparathy-
roidism emerges in the early stages of chronic
kidney disease [24]. In patients with end-stage
renal disease, secondary hyperparathyroidism is
considered an important risk factor in the patho-
genesis of CAD leading to vascular calcification
[25]. In hemodialysis patients, the use of active
vitamin D and synthetic vitamin D analogs has
been shown to reduce the risk of death from car-
diovascular disease [26]. In the general popula-
tion, the presence of vascular calcification is a
predictor of poorer five-year survival rates [27].
Interestingly, the use of calcitriol was found to
be inversely correlated with the extent of vascular
calcification, independently from other risk factors
for ischemic heart disease [28].Figure 1. The relationship between vHowever, whether enough evidence exists to
consider vitamin D deficiency as an independent
risk factor for cardiovascular diseases is debatable.
It looks like other confounding factors may impact
this association, such as HTN and gender.
In a nonrandomized prospective study of 1739
Framingham Offspring Study participants without
prior cardiovascular disease, individuals with low
25(OH) D levels and defined as: <37.5 nmol/l had
a higher incident of a composite of myocardial
infarction, coronary insufficiency, and heart fail-
ure [adjusted hazard ratio (HR) = 1.62; (1.11–2.36);
p = 0.01] compared with those with normal levels.
However, this effect was evident only in hyperten-
sive participants [HR = 2.13; (1.30–3.48)] and not in
the normotensive ones [HR = 1.04, (0.55–1.96)] [29].
Similarly, gender seems to play a role on the
impact that vitamin D deficiency has on CAD.
While men with low 25(OH) D levels
(637.5 nmol/l) had a higher risk [relative risk
RR = 2.09 (1.24–3.54)] of myocardial infarction
compared to men with sufficient levels
(675 nmol/l) after adjustment for various lifestyle
and other risk factors, this trend was not the same
for women [30].
Nonetheless, a recent study showed that vita-
min D levels could be independently linked to
the risk of cardiovascular disease. In a cohort of
14,641 men and women living in Norfolk, United
Kingdom, aged 42–82, during the period between
1997 and 2000, and who were followed up to
2012, an increase of 20-nmol/L 25(OH) D levels
was associated with HR of 0.92 ([0.88–0.96];
p < 0.001) for total mortality and 0.96 ([0.93–0.99];
p = 0.014) for prevalence of cardiovascular disease,
even after adjustment for multiple variants in both
men and women [31].
Vitamin D deficiency and heart failure
There is increasing evidence that vitamin D
deficiency may be an important factor in the
pathogenesis of heart failure [17]. Vitamin D
deficiency seems to be linked to various mechan-
isms that play a significant role in the pathogenesisitamin D and CAD risk factors.
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2015;27:264–271of CHF [32]. These mechanisms include the activa-
tion of RAAS [16,33], the presence of oxidative
stress in different tissues including the skin, skeletal
muscles, heart, and peripheral blood mononuclear
cells [34], and activation of pro-inflammatory
cytokines as interleukin (IL)-8 and tumor necrosis
factor (TNF)-alpha [35].
Vitamin D suppresses the pro-inflammatory
state by downregulating nuclear factor-jB activity
and decreasing IL-6, IL-12, interferon-c, and TNF-
a production [36]. At the same time, it increases
anti-inflammatory cytokines [36]. Vitamin D defi-
ciency therefore leads to a reduction in the down-
regulation of nuclear factor-jB activity, a decrease
in IL-10 production, and an increase in IL-6, IL-12,
interferon-c, and TNF-a production, all of which
lead to the pro-inflammatory state of CHF
(Fig. 2) [36].
The level of vitamin D is linked to many of
the clinical and laboratory parameters of CHF,Figure 2. Vitamin D deficiency role in the p
Figure 3. The relationship between vitamin D levels and the cliincluding the New York Heart Association
(NYHA) functional classifications, NT pro-BNP
(N-terminal of the prohormone brain natriuretic
peptide), NT-proANP (N-terminal of the prohor-
mone atrial natriuretic peptide) and even LVEF
(left ventricle ejection fraction); (Fig. 3). In the
Ludwigshafen Risk and Cardiovascular Health
(LURIC) prospective cohort study of 3299 con-
secutive male and female patients scheduled for
coronary angiography, the levels of NT-pro-BNP
was significantly inversely correlated with those
of 25(OH) D (correlation coefficient R = 0.190;
p < 0.001) and calcitriol (R = 0.253; p < 0.001)
[37]. Even after multivariable adjustments for
multiple potential confounding factors, the
inverse correlation of NTpro-BNP with 25(OH) D
and calcitriol levels was still observed (b coeffi-
cient =0.082; p < 0.001) and (b coefficient=0.180;
p < 0.001) respectively [37,38]. Similarly, in CHF
patients, the levels of 25(OH) D and calcitriol wereathogenesis of congestive heart failure.
nical and laboratory parameters of congestive heart failure.
R
EV
IE
W
 A
RT
IC
LE
J Saudi Heart Assoc
2015;27:264–271
FANARI ET AL 269
VITAMIN D DEFICIENCY PLAYS AN IMPORTANT ROLE IN CARDIAC DISEASE
AND AFFECTS PATIENT OUTCOME: STILL A MYTH OR A FACT THAT NEEDS
EXPLORATION?also inversely correlated with NT-proANP
(r2 = 0.16; p < 0.001 and r2 = 0.12; p < 0.01, respec-
tively) [39].
Further, vitamin D level was linked to left ven-
tricle function. 25(OH) D and calcitriol levels were
inversely correlated with impaired left ventricle
function (p < 0.001 for both), and this association
remained significant after multivariable adjust-
ments (p < 0.001 for both) [37]. Similarly, higher
NYHA classes were also associated with lower
levels of 25(OH) D and calcitriol (p < 0.001 for
both) [37].
On the other hand, a recent study that followed
3731 men aged 60–79 years prospectively with no
prevalent heart failure and followed up for a mean
period of 13 years showed that the risk of develop-
ing heart failure was linked to Parathyroid
Hormone (PTH) level rather than those of 25(OH)
D. Elevated PTH (P55.6 pg/mL) was associated
with significantly higher risk of incident HF after
adjustment for lifestyle characteristics and comor-
bidities (HR = 1.66; [1.30–2.13]). In contrast, the
correlation between 25(OH) D levels and incident
HF was not significant [40].
Vitamin D deficiency and stroke
As mentioned earlier, vitamin D deficiency is
linked to many of the well-established risk factors
for atherosclerosis and ischemic stroke, including
diabetes, HTN, and hyperlipidemia [21–23]. Fur-
thermore, a recent study linked some genotypes
of VDR to increased risk of stroke [15]. Vitamin
D deficiency also appears to be associated with
increased risk of chronic cerebral small vessel dis-
ease [41]. A recent study of 59 consecutive patients
with acute ischemic stroke or transient ischemic
attack who underwent magnetic resonance imag-
ing of the brain showed that 25(OH) D levels
below 25 nmol/L was associated with lacunes
(regression coefficient, 0.5; 95% CI, 0.04–0.95), sev-
ere white matter hyperintensity (OR = 2.74; [1.31–
6.45]), and deep cerebral microbleeds (OR = 1.68;
[1.03–2.78]) [41].
The impact of vitamin D level on cardiovascular
outcomes
Vitamin D deficiency was linked to increased
risk of death and cardiovascular death in multiple
studies. Follow-up of the 3258 participants in the
LURIC study over a median period of 7.7 years
showed that patients with severe and moderate
vitamin D deficiency (median levels of 25(OH) D
of 19.0 and 33.3 nmol/l) had higher incidence of
death [HR = 2.08, (1.60–2.70) and HR = 1.53 (1.17–
2.01), respectively, and cardiovascular death[HR = 2.22; (1.57–3.13) and HR = 1.82 (1.29–2.58),
respectively, when compared to patients with nor-
mal levels (median levels of 71.0 nmol/l). Similar
results were obtained for patients in the lowest
calcitriol quartile [38,42].
The follow-up of 1739 Framingham Offspring
Study participants without prior cardiovascular
disease with vitamin D deficiency over a mean of
5.4 years showed an increased risk of and a con-
siderably high cardiovascular event (composite
of death, myocardial infarction, stroke and CHF)
rate of 6.9%. Lower levels of 25(OH) D of 15 ng/
mL were associated with higher risk of cardiovas-
cular events [HR = 2.04 (1.42–2.940; p < 0.001) com-
pared to the rest of the cohort [29]. Similarly, the
University of Utah study showed an increased risk
of cardiac events including death (HR = 1.77,
p < 0.0001), coronary artery disease (HR = 1.45,
p < 0.0001), heart failure (HR = 2.01, p < 0.0001),
and stroke (HR = 1.78, p = 0.004) in vitamin D defi-
cient individuals [22].
The Heart and Soul Study followed 946 par-
ticipants with stable cardiovascular disease in
San Francisco, California for a median of eight
years and recently reported that levels less than
20 ng/mL remained independently associated
with cardiovascular events (HR = 1.30 [1.01–1.67])
even after adjustment for socio-demographic
factors, season of blood measurement, health
behaviors, and comorbid conditions [43].Conclusion
There is increasing evidence that vitamin D defi-
ciency may be an important and hitherto neglect-
ed factor in the pathogenesis of cardiovascular
disease. Vitamin D deficiency is related to a broad
spectrum of cardiovascular disease and its risk
factors. Furthermore, it is associated with
increased morbidity and mortality. Vitamin D
supplementation may play a role in decreasing
morbidity and mortality of cardiovascular disease.
Further studies on that role may be warranted.References
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